Sight Sciences, INC Form 4 insider transactions

Sight Sciences, Inc. President and CEO, Paul Badawi, sold 37,226 shares of common stock across two transactions in early January 2026 to cover tax liabilities from restricted stock unit vesting.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 11,170 shares of common stock across two transactions in early January 2026 to cover tax liabilities from restricted stock unit vesting.

Sight Sciences' Chief Technology Officer, David Badawi, sold 9,660 shares of common stock across three transactions in early January 2026 to cover tax liabilities from restricted stock unit vesting.

Sight Sciences CFO James Rodberg sold 4,999 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Sight Sciences' Chief Operating Officer, Alison Bauerlein, sold a total of 20,543 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Sight Sciences' EVP of Operations & R&D, Brenton Taylor, sold 619 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Sight Sciences' Chief Technology Officer, David Badawi, exercised stock options to acquire 21,270 shares of common stock, increasing his direct beneficial ownership.

Sight Sciences' Chief Technology Officer, David Badawi, filed an amended Form 4 to correct previously reported beneficial ownership of common stock and derivative securities.

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc., purchased 13,958 shares of common stock at an average price of $8.308 per share.

Sight Sciences CFO James Rodberg sold 2,518 shares of common stock at a weighted average price of $8.25 to cover tax obligations related to restricted stock unit vesting.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, exercised stock options and subsequently sold 44,850 shares of common stock for approximately $8.08 per share, as part of a Rule 10b5-1 plan related to a marital separation agreement.

Sight Sciences' EVP of Operations & R&D, Brenton Taylor, sold 14,418 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 3,150 shares of common stock for $8.01 per share following option exercises, with proceeds going to his former spouse as part of a marital separation agreement.

Sight Sciences' Chief Operating Officer, Alison Bauerlein, received a grant of 23,006 restricted stock units valued at approximately $150,000.

Sight Sciences' Chief Financial Officer, James Rodberg, was granted 15,337 restricted stock units, valued at approximately $100,000, under the company's 2021 Incentive Award Plan.

Brenton Taylor, EVP of Operations & R&D at Sight Sciences, sold 591 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Sight Sciences Chief Financial Officer Alison Bauerlein sold 19,948 shares of common stock at $3.30 per share to cover tax liabilities from restricted stock unit vesting.

Sight Sciences' President and CEO, Paul Badawi, sold 24,441 shares of common stock on October 1, 2025, to cover tax liabilities from restricted stock unit vesting.

Sight Sciences' Chief Technology Officer, David Badawi, sold 6,033 shares of common stock at $3.27 per share to cover tax obligations related to restricted stock unit vesting.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 9,731 shares of common stock at $3.27 per share to cover tax obligations related to RSU vesting.

Catherine Mazzacco, a Director at Sight Sciences, Inc., transferred 37,492 shares of common stock to an irrevocable trust for no consideration.

Sight Sciences' EVP of Operations & R&D, Brenton Taylor, received a grant of 25,840 Restricted Stock Units valued at approximately $100,000.

Matthew Link, Chief Commercial Officer of Sight Sciences, Inc., has resigned from his position effective August 31, 2025.

Manohar K. Raheja, EVP of Research & Development at Sight Sciences, Inc., has terminated employment, ending his Section 16 reporting obligations.

Sight Sciences, Inc. Chief Technology Officer and Director David Badawi reported the exercise of 40,000 stock options at $0.12 per share, effective July 17, 2025, increasing his direct beneficial ownership to 1,871,025 shares of common stock.

Sight Sciences, Inc.'s Chief Legal Officer, Jeremy B. Hayden, sold 9,160 shares of common stock on July 3, 2025, to cover tax liabilities related to restricted stock unit vesting.

Sight Sciences, Inc.'s Chief Financial Officer, Alison Bauerlein, sold 19,260 shares of common stock at $4.098 per share to cover tax liabilities related to restricted stock unit vesting.

Sight Sciences, Inc. President and CEO Paul Badawi sold 23,637 shares of common stock on July 1, 2025, at a weighted average price of $4.152 per share to cover tax obligations related to restricted stock unit vesting.

Sight Sciences, Inc.'s Chief Technology Officer, David Badawi, sold 5,679 shares of common stock for $4.174 per share to cover tax obligations related to restricted stock unit vesting.

Sight Sciences' Chief Commercial Officer, Matthew Link, sold 4,889 shares of common stock at $4.098 per share to cover tax obligations related to restricted stock unit vesting.